MedDataX Logo

Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype

NCT ID: NCT04470726

Last Updated: 2024-12-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-18

Study Completion Date

2023-07-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate safety and efficacy of AIV001 treatment on low-risk Nonmelanoma Skin Caner of the basal cell carcinoma subtype.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AIV001 (axitinib) has been formulated to provide focal disease-modifying therapy for patients with nonmelanoma skin cancer (NMSC) of the basal cell carcinoma (BCC) subtype. AIV001 targets angiogenesis, inflammation, and fibrosis associated with various pathological skin conditions and was formulated as a simple intradermal/intratumoral injection demonstrating prolonged skin residence. Surgical excision is the standard treatment for NMSC of the basal cell carcinoma subtype for lesions of \< 20 mm. Surgical removal of lesions is effective but for some patients unwilling or contraindicated for surgery a nonsurgical option is needed. A nonsurgical option will eliminate post-surgical complications and scarring experienced after lesion removal. Also, specific anatomical location of lesions present cosmesis (i.e., face) or healing challenges (i.e., lower limbs). An effective injectable will benefit patients who are averse to surgery, at risk of wound healing complications or concerned with cosmesis outcomes or fatigued from multiple surgeries. Patient populations (i.e., elderly or patients with diabetes) who are at risk of delayed wound healing would benefit from an injectable option. This study will evaluate injection methods, interval of treatment, four ascending doses, safety, histological clearance and clinical clearance of biopsy-confirmed "low-risk" BCC lesion of \<20 mm located on non-facial skin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Superficial Basal Cell Carcinoma Nodular Basal Cell Carcinoma Nonmelanoma Skin Cancers

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Nonmelanoma Skin Cancer Keratinocyte Carcinoma NMSC BCC basal cell carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Subjects will be treated once, twice or three times at 21 days interval and lesions examined at the end of the study investigators will evaluate the lesion surface area for clearance and excise the original lesion area for histological assessment.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AIV001 Treatment Dose 1

Intradermal/intratumoral, Dose 1

Group Type EXPERIMENTAL

AIV001

Intervention Type DRUG

Intradermal/intratumoral

AIV001 suspension

Intervention Type DRUG

AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection

AIV001 Treatment Dose 2

Intradermal/intratumoral, Dose 2

Group Type EXPERIMENTAL

AIV001

Intervention Type DRUG

Intradermal/intratumoral

AIV001 suspension

Intervention Type DRUG

AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection

AIV001 Treatment Dose 3

Intradermal/intratumoral, Dose 3

Group Type EXPERIMENTAL

AIV001

Intervention Type DRUG

Intradermal/intratumoral

AIV001 suspension

Intervention Type DRUG

AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection

AIV001 Treatment Dose 4

Intradermal/intratumoral, Dose 4

Group Type EXPERIMENTAL

AIV001

Intervention Type DRUG

Intradermal/intratumoral

AIV001 suspension

Intervention Type DRUG

AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AIV001

Intradermal/intratumoral

Intervention Type DRUG

AIV001 suspension

AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female, aged 18 to 80 years, inclusive
2. No clinically relevant abnormalities identified by a detailed medical history and vital signs
3. Presence of a histologically confirmed low risk BCC lesion, with well-defined borders, and with a largest diameter measure before biopsy of 5 mm to 20 mm, located on arms or trunk
4. Histological diagnosis of the target lesion must have been conducted 5 to 30 days prior to Day 1
5. No other dermatological disease within 50 mm of the target lesion at Day 1
6. No prior or concurrent treatment of the target lesion (including radiation therapy)
7. Willing to undergo surgical excision approximately 63 days after first treatment.

Exclusion Criteria

1. History or presence of systemic cancer
2. Prior radiation treatment at the lesion site or anywhere else on the body within the past 20 years
3. Concurrent disease or treatment that suppresses the immune system (eg, previous organ transplant history, etc.)
4. Clinically relevant cardiovascular, endocrine, hepatic, neurologic, renal, or other major systemic disease that could complicate execution of the protocol or interpretation of the study results.
5. History of thrombotic events, hemorrhagic events, and gastrointestinal perforation and fistula
6. History of recurrence or presence of any other tumor subtype in the target lesion
7. Concurrent presence of a malignant lesion within 100 mm of the target lesion that will require treatment during the study
8. Current enrollment in any other investigational drug or device study within 60 days of Day 1 of this study
9. Evidence of dermatological disease or confounding dermatological condition that would hinder carrying out the study or interpreting the results (eg, atopic dermatitis, eczema, psoriasis, xeroderma pigmentosa, etc.)
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AiViva BioPharma, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

California Dermatology & Clinical Research Institute

Encinitas, California, United States

Site Status

Island Dermatology

Newport Beach, California, United States

Site Status

Skin Surgery Medical Group

San Diego, California, United States

Site Status

Austin Institute for Clinical Research

Pflugerville, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AIV001-C01

Identifier Type: -

Identifier Source: org_study_id